Jodi Cook

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

N.V. Organon engages in the development, manufacture, and sale of prescription medicines. It offers products for cardiovascular diseases, fertility, gynecology, anesthesia, respiratory, consumer health care, neuroscience as well as immunology, animal health, and oncology. Its products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. The company was founded in 1923 and is headquartered in Oss, the Netherlands.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

Millennium Management LLC is a SEC-investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Israel 'Izzy' Englander in 1989 and is a subsidiary of MLM Trust B LLC, itself a subsidiary of MLM Trust B. Millennium Management provides discretionary investment advisory services to private investment funds.

Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ.

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

DNA Group, Inc. manufactures and sells HMI, connectivity and illumination products. It offers simple on/off switches to sophisticated electronic controls and solutions. The company was founded by Eric Vaughn and is headquartered in Raleigh, NC.

Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland.

Sirius Healthcare Partners GmbH provides independent advice to small and mid-cap healthcare companies, venture capital firms, institutional and private investors. The firm's services include strategic advisory, mergers and acquisition and financing advisory. It serves in the area of biotechnology, medical technology and diagnostics, platform technologies and healthcare markets. The company was founded by Subhasis Roy, Khalid Islam, Ernesto Mancosu, Werner Tschollar, Andreas Vogler and Mikael von Euw and is headquartered in Zurich, Switzerland.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

Prev AbR LLC develops biologic and beta-lactamase compounds. The private company is based in Bethesda, MD. The company was founded by Khalid Islam.

Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland.

Commave Therapeutics SA is a Swiss pharmaceutical manufacturing company. The private company is based in Geneva, Switzerland.

Naicons Srl develops a game-changing drug discovery platform. The private company is based in Milan, Italy.

GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland.

Elion Oncology, Inc. engages in the provision of pharmaceutical services. The company was founded in 2016 and is headquartered in Bethesda, MD.